Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity
January 07, 2025 11:00 ET
|
Zealand Pharma
Press Release – No. 2 / 2025 Steven R. Smith, MD, joins Zealand Pharma as Senior Global Medical Advisor in Obesity Copenhagen, Denmark, January 7, 2025 – Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL)...
Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th
January 06, 2025 11:00 ET
|
Zealand Pharma
Press Release – No. 1 / 2025 Zealand Pharma to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13th Copenhagen, Denmark, January 6, 2025 – Zealand Pharma A/S (CVR-no....
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
December 25, 2024 11:40 ET
|
Zealand Pharma
Company announcement – No. 53 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
December 25, 2024 11:30 ET
|
Zealand Pharma
Company announcement – No. 52 / 2024 Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq:...
U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome
December 19, 2024 14:58 ET
|
Zealand Pharma
Company announcement – No. 51 / 2024 U.S. Food and Drug Administration issues Complete Response Letter for the glepaglutide New Drug Application for the treatment of short bowel syndrome The FDA...
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
December 10, 2024 09:00 ET
|
Zealand Pharma
Press Release – No. 12 / 2024 Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Zealand Pharma announces that the...
Zealand Pharma to participate in the Jefferies London Healthcare Conference
November 13, 2024 12:00 ET
|
Zealand Pharma
Press Release – No. 11 / 2024 Zealand Pharma to participate in the Jefferies London Healthcare Conference Copenhagen, Denmark, November 13, 2024 – Zealand Pharma A/S (CVR-no. 20045078),...
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
November 11, 2024 11:00 ET
|
Zealand Pharma
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons ...
Zealand Pharma Announces Financial Results for the First Nine Months of 2024
November 07, 2024 01:00 ET
|
Zealand Pharma
Company announcement – No. 49 / 2024 Zealand Pharma Announces Financial Results for the First Nine Months of 2024 Continued strong progress across obesity pipeline with proprietary assets ready for...
Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results
November 01, 2024 12:30 ET
|
Zealand Pharma
Press Release – No. 10 / 2024 Zealand Pharma conference call on November 7 at 2pm CET (8am ET) to present third quarter 2024 financial results Copenhagen, Denmark, November 1,...